We explored both epigenetic silencing of RASSF1A in patients with IBD, and if the intracellular NOD2 pathogen recognition receptor/RIPK2 pathway may be driving the inflammation in the colon of IBD patients. Here, RIPK2 is linked to inflammatory bowel disease.